107 related articles for article (PubMed ID: 1965755)
21. Immunolocalisation of cytochrome P-450 3A enzymes in human breast carcinoma: relationship with tumour differentiation and steroid receptors.
Galant C; Gala JL; Van Den Berge V; Berlière M; Haumont E; Horsmans Y
Pharmacol Toxicol; 2001 Mar; 88(3):142-6. PubMed ID: 11245409
[TBL] [Abstract][Full Text] [Related]
22. Expression of ER, Ki-67 and cylinD1 in the pre-cancerous breast of Chinese patients.
Zhou CJ; Zhang QH; Zhang TG; Sun SZ; Li H; Wang Y; Liu ZY
Pathol Oncol Res; 2009 Jun; 15(2):153-8. PubMed ID: 18941930
[TBL] [Abstract][Full Text] [Related]
23. Identification of a basal-like subtype of breast ductal carcinoma in situ.
Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
[TBL] [Abstract][Full Text] [Related]
24. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis.
Bos R; Zhong H; Hanrahan CF; Mommers EC; Semenza GL; Pinedo HM; Abeloff MD; Simons JW; van Diest PJ; van der Wall E
J Natl Cancer Inst; 2001 Feb; 93(4):309-14. PubMed ID: 11181778
[TBL] [Abstract][Full Text] [Related]
25. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters.
Thike AA; Chng MJ; Fook-Chong S; Tan PH
Pathology; 2001 Feb; 33(1):21-5. PubMed ID: 11280603
[TBL] [Abstract][Full Text] [Related]
27. Monoclonal antibody DF3 correlates with tumor differentiation and hormone receptor status in breast cancer patients.
Lundy J; Thor A; Maenza R; Schlom J; Forouhar F; Testa M; Kufe D
Breast Cancer Res Treat; 1985; 5(3):269-76. PubMed ID: 2992647
[TBL] [Abstract][Full Text] [Related]
28. Estimation of PR and ER by immunocytochemistry in breast cancer. Comparison with radioligand binding methods.
Seymour L; Meyer K; Esser J; MacPhail AP; Behr A; Bezwoda WR
Am J Clin Pathol; 1990 Oct; 94(4 Suppl 1):S35-40. PubMed ID: 1699410
[TBL] [Abstract][Full Text] [Related]
29. Growth fractions of breast cancer in relation to epidermal growth factor receptor and estrogen receptor.
Toi M; Wada T; Yamada H; Ohsaki A; Yamamoto A; Nakamura T; Niimoto M; Hattori T
Jpn J Surg; 1990 May; 20(3):327-30. PubMed ID: 2162976
[TBL] [Abstract][Full Text] [Related]
30. Aberrant P-cadherin expression: is it associated with estrogen-independent growth in breast cancer?
Paredes J; Milanezi F; Reis-Filho JS; Leitão D; Athanazio D; Schmitt F
Pathol Res Pract; 2002; 198(12):795-801. PubMed ID: 12608656
[TBL] [Abstract][Full Text] [Related]
31. Mean nuclear area and metallothionein expression in ductal breast tumors: correlation with estrogen receptor status.
El Sharkawy SL; Farrag AR
Appl Immunohistochem Mol Morphol; 2008 Mar; 16(2):108-12. PubMed ID: 18227734
[TBL] [Abstract][Full Text] [Related]
32. PCNA/cyclin expression in breast carcinomas: its relationships with Ki-67, ER, PgR immunostainings and clinico-pathologic aspects.
Tuccari G; Rizzo A; Muscarà M; Giuffrè G; Barresi G
Pathologica; 1993; 85(1095):47-55. PubMed ID: 8100059
[TBL] [Abstract][Full Text] [Related]
33. Oestrogen receptors in human breast cancer: review of histopathological correlations and critique of histochemical methods.
Underwood JC
Diagn Histopathol; 1983; 6(1):1-22. PubMed ID: 6307615
[TBL] [Abstract][Full Text] [Related]
34. A combined histological, immunocytochemical and biochemical approach in the evaluation of estrogen receptors in breast carcinomas.
Pietribiasi F; Gugliotta P; Racca S; Di Carlo F; Bussolati G
Int J Biol Markers; 1986; 1(1):9-14. PubMed ID: 2826620
[TBL] [Abstract][Full Text] [Related]
35. 17 beta-Hydroxysteroid dehydrogenase type 1 and type 2 in ductal carcinoma in situ and intraductal proliferative lesions of the human breast.
Ariga N; Moriya T; Suzuki T; Kimura M; Ohuchi N; Satomi S; Sasano H
Anticancer Res; 2000; 20(2B):1101-8. PubMed ID: 10810403
[TBL] [Abstract][Full Text] [Related]
36. Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer.
Järvinen TA; Pelto-Huikko M; Holli K; Isola J
Am J Pathol; 2000 Jan; 156(1):29-35. PubMed ID: 10623650
[TBL] [Abstract][Full Text] [Related]
37. Endocrine ductal carcinoma in situ (E-DCIS) of the breast: a form of low-grade DCIS with distinctive clinicopathologic and biologic characteristics.
Tsang WY; Chan JK
Am J Surg Pathol; 1996 Aug; 20(8):921-43. PubMed ID: 8712293
[TBL] [Abstract][Full Text] [Related]
38. Extensive intraductal component (EIC) and estrogen receptor (ER) status in breast cancer.
Jing X; Kakudo K; Murakami M; Nakamura Y; Nakamura M; Yokoi T; Oura S; Sakurai T
Pathol Int; 1998 Jun; 48(6):440-7. PubMed ID: 9702856
[TBL] [Abstract][Full Text] [Related]
39. Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast.
Gonzalez LO; Corte MD; Junquera S; Bongera M; Rodriguez JC; Vizoso FJ
Histopathology; 2007 Jun; 50(7):866-74. PubMed ID: 17543076
[TBL] [Abstract][Full Text] [Related]
40. VEGF expression is associated with negative estrogen receptor status in patients with breast cancer.
Fuckar D; Dekanić A; Stifter S; Mustać E; Krstulja M; Dobrila F; Jonjić N
Int J Surg Pathol; 2006 Jan; 14(1):49-55. PubMed ID: 16501835
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
